课题基金 / 基金详情

An attempt to clarify the cause of "Pokkuri disease", a special type of sudden cardiac death, via Forensic Medicine.

An attempt to clarify the cause of "Pokkuri disease", a special type of sudden cardiac death, via Forensic Medicine.
试图通过法医学阐明“Pokkuri 病”(一种特殊类型的心源性猝死)的病因。
批准号:
14570396
负责人:
TAKEICHI Sanae
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2003

项目摘要

项目成果

TAKEICHI Sanae的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Our present research has revealed the following new facts related to coronary spasm, which we believe is the direct cause of Pokkkuri disease.1.We have clarified the role of endothelium-derived nitric oxide (NO)on coronary artery spasm by RLP isolated from the sudden cardiac death(SCD) cases. NO production in bovine endothelial cells was inhibited by RLP in a dose dependent manner. The amount of NO synthase (eNOS) was not dicreased, but the enzyme activity was suppressed by RLP.2.Recently the increased activity of Rho-kinase in vascular smooth muscle cells has been known to play a major role in the pathogenesis of coronary artery spasm. Our in vivo study demonstrated that long -term treatment with RLP, but not with nascent VLDL from patients with SOD markedly enhanced coronary vasospastic activity in porcine coronary arteries. We then demonstrated in cultured human coronary vascular smooth muscle cells that the treatment of RLP significantly enhanced the expression and activation of Rho-kinase. Rho-kinase inhibitor, hydoxyfasdil completely inhibited this effect.3.Validity of postmortem plasma remnant lipoprotein assay was studied in order to confirm the analysis of postmortem plasma. The postmortem alteration of lipids and lipoproteins were observed by the following methods ; Dry Chem TG and Determiner L-TG assay, HPLC profile analysis, electrophoresis, electron microscopy and rabbit ante-and postmortem plasma. We found that plasma lipid and lipoprotein levels determined in postmortem state did not differ significantly from antemortem levelsIn addition to the above results4.We have found that hypertriglyceridemia in pregnancy did not contribute to the elevation of RLP-C/VLDL-C ratio and RLP-TG/VLDL-TG ratio. These ratios were significantly low in pregnancy compared with diabetic patients and other cardiovascular disease. These results strongly point to the fact that Pokkuri disease is more common in males than in females.
期刊论文(58)
专著(0)
科研奖励(0)
会议论文
Takeichi S.他6名: "Valodity of plasma remnant lipoproteins as surrogate markers of antemortem level in cases of sudden coronary death"Clin.Chim.Acta. In press. (2004)
Takeichi S. 和其他 6 人:“在猝死的情况下,血浆冠状动脉残余脂蛋白作为生前水平的替代标记物的有效性”(Clin.Chim.Acta)(2004 年)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Takeichi Sanae et al.: "Validity of plasma remnant lipoproteins as surrogate markers of antemortem level in cases of sudden coronary death"Clin Chimi Acta. In press. (2004)
Takeichi Sanae 等人:“血浆残余脂蛋白作为冠心病猝死病例中生前水平替代标志物的有效性”Clin Chimi Acta。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Ohara N., Takeichi S., Naito Y., Nakajima Y., Yukawa N., Nakano T., Nakajima K.: "Remnant-like particles from subjects who died of coronary artery disease suppress NO synthase activity and attenuate endothelium-dependent vasorelaxation"Clin.Chim.Acta. 338
Ohara N.、Takeichi S.、Naito Y.、Nakajima Y.、Yukawa N.、Nakano T.、Nakajima K.:“死于冠状动脉疾病的受试者的残留样颗粒抑制 NO 合酶活性并减弱内皮依赖性
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
29
    Overview of sudden death in Japan and the role of plasma remnant lipoproteins, the new risk factor, in the prevention of sudden cardiac death
    • 批准号:
      10557048
    • 项目类别:
      Grant-in-Aid for Scientific Research (B).
    • 资助金额:
      $8.9万
    • 财政年份:
      1998
    • 负责人:
      TAKEICHI Sanae
    • 依托单位:
    The possible role of Remnant Lipoproteins as a risk factor for Sudden Cardiac Death
    • 批准号:
      07807050
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.09万
    • 财政年份:
      1995
    • 负责人:
      TAKEICHI Sanae
    • 依托单位: